Role of the PNPLA3 polymorphism rs738409 on silymarin + vitamin E response in subjects with non-alcoholic fatty liver disease

Aller, Rocío; Laserna, Cristina; Rojo, Miguel Ángel; Mora, Natalia; García Sánchez, Concepción; Pina, María; Sigüenza, Rebeca; Durà, Miguel; Primo, David; Izaola, Olatz; Luis, Daniel de.
Rev. esp. enferm. dig ; 110(10): 634-640, oct. 2018. tab, graf
Artículo en Inglés | IBECS (España) | ID: ibc-177819

Documentos relacionados

  1. Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies.
  2. Chromosome-level genome assembly of the Muscovy duck provides insight into fatty liver susceptibility.
  3. Hope on the Horizon: Promising Therapies for Steatotic Liver Disease.
  4. In vitro assessment of nutraceutical compounds and novel nutraceutical formulations in a liver-steatosis-based model.
  5. THE INFLUENCE OF PLACENTAL DRUG LAENNEC ON MOTOR FUNCTION OF THE BILIARY TRACT IN PATIENTS WITH FATTY DEGENERATION OF LIVER.
  6. Transcription profiling of cadmium-exposed livers reveals alteration of lipid metabolism and predisposition to hepatic steatosis.
  7. Pediatricians' practices and knowledge of metabolic dysfunction-associated steatotic liver disease: An international survey.
  8. Pathophysiology of non-alcoholic steatohepatitis and basis for treatment.
  9. [Study of clinical efficiency of essential phospholipids and silymarin combination in nonalcoholic and alcoholic steatohepatitis].
  10. [Nonalcoholic fatty liver disease. A current perspective].